Form 4: Kezar Life Sciences Director's Ownership Changes Post-Merger

Kezar Life Sciences reports changes in beneficial ownership for Director Graham K. Cooper following the company's merger completion on May 11, 2026.

Summary

• This filing details changes in beneficial ownership for Graham K. Cooper, a Director at Kezar Life Sciences, Inc. (KZR).
• The changes are a result of the company's merger, which was completed on May 11, 2026.
• Specifically, stock options held by Mr. Cooper were cancelled as part of the merger agreement.
• Options with an exercise price equal to or greater than $6.955 per share were cancelled without consideration.
• Options with an exercise price less than $6.955 per share were converted into the right to receive a cash payment and a Contingent Value Right (CVR) per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of ownership changes following a completed merger and does not provide new financial performance data or strategic guidance.

Positives

• Director Graham K. Cooper's options that were 'in-the-money' were converted into cash and CVRs, providing potential value realization.
• The merger has been completed, signifying a significant corporate event.

Negatives

• All 'out-of-the-money' stock options held by Director Graham K. Cooper were automatically cancelled and ceased to exist without any consideration.
• The specific cash amounts and CVRs received are not detailed in this filing, only the mechanism of conversion.

Risks

• The value of the CVRs is contingent and not guaranteed, representing a potential future risk for the value received.
• The cancellation of out-of-the-money options represents a loss of potential future upside for the reporting person.

Future Outlook

The future outlook for the value of the Contingent Value Rights (CVRs) is dependent on the performance and milestones achieved by the surviving entity post-merger, as detailed in the Merger Agreement.

Management Comments

• The filing is a procedural statement of changes in beneficial ownership and does not contain direct management comments on the financial performance or strategic outlook.

Industry Context

StockSavvy.ai notes that the cancellation and conversion of stock options in the context of a merger is a standard practice, designed to align executive and director compensation with the transaction's terms and provide value to option holders based on the deal's economics.

Stakeholder Impact

• Shareholders: The merger's completion signifies a change in equity ownership structure. The value of CVRs will impact former option holders.
• Employees: Those holding in-the-money options may receive cash and CVRs, while those with out-of-the-money options will not receive further compensation from those awards.
• Directors: Graham K. Cooper, as a director, has had his stock options treated according to the merger agreement, with in-the-money options converted and out-of-the-money options cancelled.

Next Steps

• Shareholders and option holders will await the realization of value from the CVRs, if any.
• The surviving entity will continue operations under the new ownership structure.

Key Dates

Keywords

Kezar Life Sciences, KZR, Form 4, SEC Filing, Beneficial Ownership, Stock Options, Merger, Director, Graham K. Cooper, CVR, Contingent Value Right